drugset / Trial / NCT06444243

Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT06444243

RandomizedParallel-groupDouble-blindOther

Summary

To explore the effectiveness of psilocybin-assisted therapy on reducing alcohol consumption in a double-blind, randomised, phase II clinical trial.

Timeline

Start
2024-09
Primary completion
2025-07
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Niacin Small molecule 250 mg
Subject Psilocybin Other / unclassified 25 mg